Tscan Therapeutics, Inc. · NASDAQ:TCRX

Tscan Therapeutics — Technical Presentation (December 2025)

30 slides from Tscan Therapeutics's technical presentation, Dec 8, 2025

  1. Slide 1: Virtual KOL Event to Discuss Updated Data from the ALLOHA Phase 1 Heme Trial

    Virtual KOL Event to Discuss Updated Data from the ALLOHA Phase 1 Heme Trial and Market Opportunity for TSC-101 December 8, 2025

  2. Slide 2: Disclaimers and forward-looking statements

    Disclaimers and forward-looking statements This presentation and the accompanying discussion contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding the Company’s plans, prog

  3. Slide 3: Agenda

    Agenda Welcome and Overview of Heme Program Gavin MacBeath, Ph.D. Updated Data from Phase 1 ALLOHATM Trial Ran Reshef, M.D., M.Sc. Manufacturing Update and Pivotal Trial Design for TSC-101 Gavin MacBeath, Ph.D. Market Opportunity for TSC-101 and Follow-on Product Candidates Stephen Camiolo, BSN, ACN

  4. Slide 4: TScan is a fully integrated, next-generation TCR-T cell therapy company

    TScan is a fully integrated, next-generation TCR-T cell therapy company Clinical Preclinical Discovery HEME MALIGNANCY PROGRAM SOLID TUMOR PROGRAM AUTOIMMUNITY PROGRAM • Targets residual disease to prevent • First patients dosed with multiplex • TScan’s proprietary platform enables relapse in patien

  5. Slide 5: Heme Malignancies: Targeting residual disease to prevent relapse

    Heme Malignancies: Targeting residual disease to prevent relapse in patients undergoing allogeneic HCT

  6. Slide 6: TScan is working to treat residual disease and prevent relapse in heme malignancies

    TScan is working to treat residual disease and prevent relapse in heme malignancies Allogeneic hematopoietic cell transplant Current Standard (Allo-HCT) is the only potential cure for of Care patients with AML and MDS 38-44% of patients relapse within two years Unmet Medical following Allo-HCT with

  7. Slide 7: TSC-101 is a TCR-T cell therapy designed to eliminate residual cancer and prevent relapse

    TSC-101 is a TCR-T cell therapy designed to eliminate residual cancer and prevent relapse following Allo-HCT TSC-101 PATIENT (HLA-A*02:01-positive) HA-2 positive Residual Cancer cancer HA-2 cell Hematopoietic cell TCR-T cell negative HA-2 transplant infusion positive Normal blood cell Stem TSC-101 D

  8. Slide 8: ALLOHA, a multi-arm Phase 1 trial for TSC-101 in AML, ALL, and MDS

    ALLOHA , a multi-arm Phase 1 trial for TSC-101 in subjects with AML, ALL, and MDS (NCT05473910) Manufacturing TSC-101 TSC-101 apheresis Infusion 1 Infusion 2 Subject Donor HCT screening screening apheresis Treatment Arm Transplant + TSC-101 Day 0 Day +21 Day +61 Control Arm Transplant alone Pre-tran

  9. Slide 9: Updated Results from the Phase 1 ALLOHA trial

    Updated Results from the Phase 1 ALLOHATM trial Data presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

  10. Slide 10: Patients in both the treatment and control arms are at high risk for relapse

    Patients in both the treatment and control arms are at high risk for relapse TSC-101 Control Enrolled Subjects 23 19 Evaluable Subjects* 19 (100%) 18 (100%) Median Time from HCT, months 13.4 (4-33) 16.1 (1-36) Age, Median (Range) 65 (52-74) 66 (23-77) Sex, Male %) 13 (68%) 9 (50%) ALL 2 (11%) 1 (6%)

  11. Slide 11: TSC-101 is well tolerated with no dose-limiting toxicity

    TSC-101 is well tolerated with no dose-limiting toxicity TSC-101 Control n=19​ n=18 Treatment-emergent aGvHD (MAGIC) 12 (63%)​ 10 (56%)​ • No DLTs reported Grade I​ 8 (42%)​ 5 (28%)​ • No moderate or severe chronic GvHD (cGVHD) Grade II​ 3 (16%)​ 4 (22%)​ with TSC-101 Grade III 1 (5%) 1 (6%) ‒ One c

  12. Slide 12: TSC-101 is associated with fewer relapses, more durable remissions, and longer survival

    TSC is associated Pre-HCT with fewer relapses, more durable remissions, and longer survival Arm Disease MRD 6 months 1 year 2 years TSC-101 DL 1 MDS p53mut P-004-0001 TSC-101 infusion TSC-101 DL2s‡ AML P-004-0005 Clinical intervention for TSC-101 DL2 B-ALL P-004-0006 TSC-101 DL3s‡ B-ALL P-004-0008 c

  13. Slide 13: TSC-101 continues to show strong activity by chimerism assays

    TSC-101 continues to show strong activity by chimerism assays TSC-101 Treatment-arm subjects Control-arm subjects DL2s DL3/ DL3/ Time DL1 ‡ DL2 DL3s‡ DL3 DL3 DL3 DL3 DL3 DL3 DL3 DL3 DL3 DL4 DL4 DL4 DL4 C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 C13 C14 C15 C16 4 4 post MDS AML B-ALL B-ALL MDS AML AML MD

  14. Slide 14: TSC-101 infusion post-relapse converted subject to complete donor chimerism and complete remission

    TSC-101 infusion post-relapse converted subject to complete donor chimerism and complete remission (CD33) chimerism %%(CD33) 25 CD33 Chimerism (CD33) 20 Whole blood • Chimerism 74-year-old (Whole male with AML Blood) in CR1 15 received 2 infusions of TSC-101 per RecipientChimerism 10 DL3 5 • 2nd inf

  15. Slide 15: Manufacturing

    Manufacturing Commercial-ready process developed that shortens manufacturing time and reduces COGs

  16. Slide 16: Some patients recently treated at dose level 4 showed incomplete chimerism

    Some patients recently treated at dose level 4 showed incomplete chimerism TSC-101 Treatment-arm subjects Control-arm subjects DL2s DL3/ DL3/ Time DL1 ‡ DL2 DL3s‡ DL3 DL3 DL3 DL3 DL3 DL3 DL3 DL3 DL3 DL4 DL4 DL4 DL4 C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 C13 C14 C15 C16 4 4 post MDS AML B-ALL B-ALL M

  17. Slide 17: Extent of ex vivo expansion may be associated with chimerism results

    Extent of ex vivo expansion in phase 1 manufacturing process may be associated with chimerism results 30 ✱ (Day 9 to harvest) • Phase 1 process required 17 days to Fold expansion 20 manufacture TSC-101 (range 14-20 days) • Mixed chimerism and relapse in the TSC- 10 101 arm appear associated with hig

  18. Slide 18: Optimized manufacturing process results in robust production with shorter time and lower COGs

    Optimized manufacturing process results in robust production with shorter time and lower COGs Phase 1 Process: 17 Days DAY 1 DAY 2 DAY 6 DAY 9 DAY 14 DAY 17 Isolate Electro- Activate Expand Enrich Expand Harvest & PBMCs porate T-cells T-cells TCR-T cells TCR-T cells Freeze Magnetic bead selection In

  19. Slide 19: Commercial-ready manufacturing process requires less ex vivo T-cell expansion

    Commercial-ready manufacturing process requires less ex vivo T-cell expansion 30 ✱ • New commercial-ready process reduces (Day 9 to harvest) Fold expansion manufacturing time by 5 days 20 (12 days vs. 17 days) • Clinical drug product manufactured using 10 the new process shows a significant reductio

  20. Slide 20: Heme Development Strategy

    Heme Development Strategy Targeting residual disease to prevent relapse in patients undergoing allogeneic HCT

  21. Slide 21: Pivotal trial design for TSC-101 uses a biologically-assigned control arm

    Pivotal trial design for TSC-101 uses a biologically-assigned control arm to support relapse-free survival as the primary endpoint • Company has reached agreement with the FDA to use a pivotal trial design that mirrors the ALLOHA Phase 1 trial (NCT05473910) • All patients that are eligible for TSC-1

  22. Slide 22: Commercial opportunity

    Commercial opportunity: Clear unmet need with concentrated market and a broad range of expansion opportunities

  23. Slide 23: TSC-101 delivers a predictable, easily planned treatment journey

    TSC-101 delivers a predictable, easily planned treatment journey * * Patient enrollment Day -10 to -1 Day 0 Day 21 Discharge, Post- Day 61 Follow up Reduced Intensity HCT transplant Infusion 1 treatment monitoring Infusion 2 (Referrals to ATCs) & follow up Conditioning • Referral to existing transpl

  24. Slide 24: TSC-101 is a first-in-class TCR-T therapy with an exciting commercial opportunity

    TSC-101 is a first-in-class TCR-T therapy with an exciting commercial opportunity Strong Value Proposition: TSC-101 has positive early efficacy & safety data, addressing a major unmet need in the post-transplant setting where no therapeutic agents are approved Streamlined Commercial Commercial-Ready

  25. Slide 25: TSC-101 could generate $1 billion+ annually at peak penetration in the U.S.

    TSC-101 could generate $1 billion+ annually at peak penetration in the U.S. Addressable U.S. Patient Population at Launch 6,200 AML/MDS patients undergoing $1.4B+ Allo HCT peak revenue 2,600 HLA-A*02:01 positive patients (42%) ~2,100 with A*02-negative donor (80%) 2.1k addressable U.S. patients at l

  26. Slide 26: Current clinical trial sites include large transplant centers

    Current clinical trial sites include large transplant centers and provide broad geographical coverage • Phase 1 currently includes 20 sites • Adding up to 10 additional sites for the pivotal study • Anticipate ~40 commercial sites at launch Current clinical trial sites on ALLOHA study

  27. Slide 27: TScan is targeting the most frequent HLAs to address a broad patient population

    TScan is targeting the most frequent human leukocyte antigens (HLAs) to address a broad patient population TSC-101 TSC-102-A0301 TSC-102-A0101 TSC-102-A2402 HLA restriction: A*02:01 A*03:01 A*01:01 A*24:02 HLA Total U.S. 2.1k (42%) 1.1k (22%) 1.2k (24%) 800 (17%) 3.9k (~78%) EU 3.9k (47%) 1.8k (25%)

  28. Slide 28: Expansion opportunities reach about 20k AML and MDS patients

    Expansion opportunities for the program provide a way to reach about 20k AML and MDS patients in North America, Europe, and APAC 25,000 Capturing an expanding treatment landscape: # of addressable patients (global) 20,000 Expansion driven by launch of products for additional HLA types.* Plan to file

  29. Slide 29: Heme Program Progress and Anticipated Milestones

    Heme Program Progress and Anticipated Milestones Reached agreement with FDA on pivotal trial design Transferred commercial-ready manufacturing process to external CDMO Two-year relapse data from initial TSC-101 patients Dec 2025 File INDs for TSC-102-A0301 and TSC-102-A0101 Q1 2026 Launch pivotal st

  30. Slide 30: Q&A

    Q&A

TScan Therapeutics — Technical Presentation (December 2025) on 6ix